Recombinant Human Interleukin-36 gamma, 169a.a.

Synonyms IL-1RP2, IL-1 epsilon, IL-1F9, IL-1H1

Accession Q9NZH8

GeneID 56300

Source Escherichia coli.

Molecular Weight Approximately 18.7 kDa, a single non-glycosylated polypeptide chain containing 169 amino acids.

Quantity 2µg/10µg/1mg

AA Sequence MRGTPGDADG GGRAVYQSMC KPITGTINDL NQQVWTLQGQ NLVAVPRSDS VTPVTVAVIT CKYPEALEQG RGDPIYLGIQ NPEMCLYCEK VGEQPTLQLK EQKIMDLYGQ PEPVKPFLFY RAKTGRTSTL ESVAFPDWFI ASSKRDQPII LTSELGKSYN TAFELNIND

Purity > 95 % by SDS-PAGE and HPLC analyses.

Biological Activity Fully biologically active when compared to standard. The specific activity is determined by its binding ability in a functional ELISA. Immobilized rHuIL-36γ at 1 µg/mL can bind recombinant human IL-1 Rrp2 Fc Chimera with a range of 0.15-5 µg/mL.

Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder.

Formulation Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

Endotoxin Less than 1 EU/μg of rHuIL-36γ, 169a.a. as determined by LAL method.

Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.

- 1 month, 2 to 8 °C under sterile conditions after reconstitution.

- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Usage This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.

Reference 1. Nicklin MJ, Barton JL, Nguyen M, et al. 2002. Genomics. 79:718-25.

2. Dinarello C, Arend W, Sims J, et al. 2010. Nat Immunol. 11:973.

3. Debets R, Timans JC, Homey B, et al. 2001. J Immunol. 167:1440-6.

4. Busfield SJ, Comrack CA, Yu G, et al. 2000. Genomics. 66:213-6.

5. Clark HF, Gurney AL, Abaya E, et al. 2003. Genome Res. 13:2265-70.

Background Interleukin-36 (IL-36) is a pro-inflammatory cytokine which plays an important role in the pathophysiology of several diseases. IL-36α, IL-36β, and IL-36γ (formerly IL-1F6, IL-1F8, and IL-1F9) are IL-1 family members that signal through the IL-1 receptor family members IL-1Rrp2 (IL-1RL2) and IL-1RAcP. IL-36γ is secreted when transfected into 293-T cells and it could constitute part of an independent signaling system analogous to interleukin-1 alpha (IL-1A), beta (IL-1B) receptor agonist and interleukin-1 receptor type I (IL-1R1). Furthermore, IL-36γ also can function as an agonist of NF-kappa B activation through the orphan IL-1-receptor-related protein 2. Recombinant human IL-36γ is synthesized as a 19 kDa, 169 amino acid (a.a.) protein that contains no signal sequence, no prosegment and no potential N-linked glycosylation site. Human to mouse, IL-36γ shares 53 % a.a. identity. Within the family, IL-36γ shares about 25 % ~ 55 % a.a. sequence identity with IL-1RA, IL-1β, IL-36RA, IL-36α, IL-37, IL-36β and IL-1F10.